News

transmission towers
How artificial intelligence can transform US energy infrastructure
Surprisingly, changing isotope masses of molybdenum in a single layer of semiconductor molybdenum disulfide was found to shift the color of light emitted when the layer was illuminated. The study revealed the potential of isotope engineering to design new technologies in 2D materials. Credit: Chris Rouleau/ORNL, U.S. Dept. of Energy
Tweaking isotopes sheds light on semiconductors
The Linac Coherent Light Source at DOE’s SLAC National Accelerator Laboratory in California reveals the structural dynamics of atoms and molecules through X-ray snapshots at ultrafast timescales. Pictured here is the LCLS-II tunnel. Credit: Jim Gensheimer/SLAC National Accelerator Laboratory
ORNL, SLAC team up for biology projects

Filter News

Area of Research

News Type

Date

News Topics

Media Contacts

Connect with ORNL

(From left) ORNL Associate Laboratory Director for Computing and Computational Sciences Jeff Nichols; ORNL Health Data Sciences Institute Director Gina Tourassi; DOE Deputy Under Secretary for Science Thomas Cubbage; ORNL Task Lead for Biostatistics Blair Christian; and ORNL Research Scientist Ioana Danciu were invited to the White House to showcase an ORNL-developed digital tool aimed at better matching cancer patients with clinical trials.

New ORNL AI tool revolutionizes process for matching cancer patients with clinical trials

OAK RIDGE, Tenn., March 4, 2019—A team of researchers from the Department of Energy’s Oak Ridge National Laboratory Health Data Sciences Institute have harnessed the power of artificial intelligence to better match cancer patients with clinical trials.

Radiochemical technicians David Denton and Karen Murphy use hot cell manipulators at Oak Ridge National Laboratory during the production of actinium-227.

ORNL ramps up production of key radioisotope for cancer-fighting drug

The Department of Energy’s Oak Ridge National Laboratory is now producing actinium-227 (Ac-227) to meet projected demand for a highly effective cancer drug through a 10-year contract between the U.S. DOE Isotope Program and Bayer.